VOR Biopharma Inc. 8-K Summary
Date Reported: November 3, 2025
Material Events: Management & Compensation
- CDO Compensation Amendment: The Company amended the employment agreement for Dr. Qing Zuraw, Chief Development Officer.
- The amendment clarifies severance terms regarding pro-rated 2025⁄2026 bonuses upon termination without cause.
- Crucially, if Dr. Zuraw resigns for any reason after December 31, 2025, she receives the same severance benefits as a termination without cause. This provision is effective for five months.